16P Repurposing rosiglitazone with chemotherapy in breast cancer: A sequence-specific synergy?

The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

“…In recent years, the involvement of PPAR-γ in other disorders such as cardiovascular disorders, [18,19] Alzheimer's, [20] and Parkinson's disease, [21] multiple sclerosis, [22] stroke, [23,24] and cancer [25,26] have been extensively exploited. These findings prompted the repurposing of troglitazone and rosiglitazone as potential anticancer agents, [27,28] which are still under clinical development. Moreover, in recent years various researchers have shown that the cardiovascular system toxicity by rosiglitazone and increased risk of bladder cancer by pioglitazone is no longer a significant issue.…”